EMEA-001877-PIP01-15-M04 - paediatric investigation plan

fremanezumab
PIPHuman

Key facts

Invented name
Ajovy
Active Substance
fremanezumab
Therapeutic area
Neurology
Decision number
P/0378/2023
PIP number
EMEA-001877-PIP01-15-M04
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Teva GmbH
E-mail: MedInfo@tevaeu.com
Tel: +44 (0)2075407117

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page